Mydecine Innovations Group (TSE:MYCO) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mydecine Innovations Group, a biotech firm focused on developing treatments for mental health disorders, has had its shares suspended from trading on the Aquis Growth Market due to non-payment of exchange fees. The company, which is pioneering next-generation medications including psychedelic compounds for conditions like PTSD and nicotine addiction, made the announcement and acknowledged its responsibility.
For further insights into TSE:MYCO stock, check out TipRanks’ Stock Analysis page.